| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| Other Sizes |
| Targets |
There is no specific biological target reported for 7-Bromo-1-tetralone. It is a chemical building block used in medicinal chemistry to synthesize potential drug candidates targeting various enzymes or receptors, such as kinases or GPCRs, depending on the final derivative.
|
|---|---|
| ln Vitro |
7-Bromotetralone is a synthetic intermediary that finds application in the manufacture of drugs.
No direct in vitro activity data is available for this compound itself. In medicinal chemistry, 7-Bromo-1-tetralone is used as a starting material to synthesize compounds with reported antiproliferative, anti-inflammatory, or antimicrobial activities. Its activity is measured indirectly via the activity of its derivatives. |
| ln Vivo |
No specific in vivo activity data is available for 7-Bromo-1-tetralone. As a synthetic intermediate, it is not intended for direct administration in animals. Any in vivo activity would be associated with the final drug candidate derived from it.
|
| Enzyme Assay |
There is no standard enzyme/receptor binding protocol for 7-Bromo-1-tetralone. It is typically characterized by analytical methods: HPLC for purity (>98%), NMR for structure confirmation, and melting point determination. No biological assay is performed on this intermediate.
|
| Cell Assay |
No specific cell-based protocol is available. If used in cell culture for preliminary screening, a general protocol would involve dissolving in DMSO (stock 10-100 mM) and diluting to 1-100 uM in culture medium. However, this compound is not typically used directly in cell assays.
|
| Animal Protocol |
No standard in vivo animal protocol exists for this compound. It is not used in live animals. General chemical safety protocols for handling halogenated aromatics apply.
|
| ADME/Pharmacokinetics |
PK properties are not applicable to this synthetic intermediate. It is lipophilic (logP ~2.5) and has low water solubility. Formulation for chemical reactions is typically in organic solvents such as DCM, THF, or DMSO.
|
| Toxicity/Toxicokinetics |
The toxicity of 7-Bromo-1-tetralone has not been fully characterized. As a halogenated aromatic compound, it may be an irritant to skin, eyes, and respiratory tract. It should be handled with appropriate personal protective equipment (gloves, goggles, lab coat) in a fume hood.
|
| Additional Infomation |
7-Bromo-1-tetralone is a versatile building block for the synthesis of tetralone-based pharmaceuticals, agrochemicals, and natural product analogs. It is used to introduce the bromine atom for subsequent cross-coupling reactions (e.g., Suzuki, Buchwald-Hartwig). This product is for research use only.
|
| Molecular Formula |
C10H9BRO
|
|---|---|
| Molecular Weight |
225.08
|
| Exact Mass |
223.983
|
| CAS # |
32281-97-3
|
| PubChem CID |
252731
|
| Appearance |
Off-white to light brown solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
311.9±31.0 °C at 760 mmHg
|
| Melting Point |
78 °C
|
| Flash Point |
103.5±12.2 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.599
|
| LogP |
3.52
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
12
|
| Complexity |
190
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CC2=C(C=C(C=C2)Br)C(=O)C1
|
| InChi Key |
YGVDCGFUUUJCDF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H9BrO/c11-8-5-4-7-2-1-3-10(12)9(7)6-8/h4-6H,1-3H2
|
| Chemical Name |
7-bromo-3,4-dihydro-2H-naphthalen-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4429 mL | 22.2143 mL | 44.4286 mL | |
| 5 mM | 0.8886 mL | 4.4429 mL | 8.8857 mL | |
| 10 mM | 0.4443 mL | 2.2214 mL | 4.4429 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
